Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Rev Clin Esp (Barc) ; 223(9): 542-551, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37717921

RESUMO

INTRODUCTION: Patients with diabetes mellitus (DM) and heart failure (HF) have a worse prognosis despite therapeutic advances in both diseases. Sodium-glucose co-transporter type 2 and GLP-1 receptor agonists have shown cardiovascular benefits and they have been positioned as the first step in the treatment of DM in patients with HF or high cardiovascular risk. However, in the pivotal trials the majority of patients receive concomitant treatment with metformin. Randomized clinical trials have not yet been developed to assess the prognostic impact of metformin at the cardiovascular level. Our objective has been centered in analyzing whether patients with DM and acute HF who receive treatment with metformin at the time of discharge may have a better prognosis at one year of follow-up. METHODS: Prospective cohort trial using the combined analysis of the two main Spanish HF registries, the EAHFE Registry (Epidemiology of Acute Heart Failure in Emergency Departments) and the RICA (National Registry of Patients with Heart Failure). RESULTS: 33% (1453) of a total of 4403 patients with DM type 2 received treatment with metformin. This group presents significantly lower mortality after one year of treatment (22 versus 32%; Log Rank test P < 0.001). In the adjusted analysis of mortality, patients receiving treatment with metformin have lower mortality at one year of follow-up regardless of the rest of the variables (RR 0,814; 95%IC 0,712-0,930; P < 0.01). CONCLUSIONS: Patients with DM type 2 and acute HF who receive metformin have a better prognosis after one year of follow-up, so we believe that this drug should continue to be a fundamental pillar in the treatment of these patients.


Assuntos
Diabetes Mellitus Tipo 2 , Insuficiência Cardíaca , Metformina , Humanos , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Metformina/uso terapêutico , Prognóstico , Estudos Prospectivos , Sistema de Registros , Hipoglicemiantes/uso terapêutico
3.
An Sist Sanit Navar ; 43(1): 93-97, 2020 Apr 20.
Artigo em Espanhol | MEDLINE | ID: mdl-32176218

RESUMO

Peripartum cardiomyopathy (PPCM) is an idiopathic cardiomyopathy that is caused by heart failure secondary to a dysfunction of the left ventricle at the end of pregnancy or in the first months following childbirth. The diagnosis is performed by electrocardiogram, radiography of the thorax and increase of natriuretic peptides. Bedside radiography can contribute with data that help early diagnosis. Treatment is carried out following clinical guidelines for heart failure, taking into account potentially teratogenic drugs. The importance of this pathology lies in that it affects women at a fertile age and is potentially mortal, which is why there must be a high index of suspicion for its diagnosis and a differential diagnosis with other entities. In this clinical note we present a series of cases of PPCM with the goal of reviewing the diagnosis and treatment of this entity.


Assuntos
Cardiomiopatias/diagnóstico , Transtornos Puerperais/diagnóstico , Adulto , Cardiomiopatias/tratamento farmacológico , Ecocardiografia , Feminino , Insuficiência Cardíaca/etiologia , Humanos , Transtornos Puerperais/tratamento farmacológico , Disfunção Ventricular Esquerda/complicações
4.
An Sist Sanit Navar ; 41(2): 263-267, 2018 Aug 29.
Artigo em Espanhol | MEDLINE | ID: mdl-29943762

RESUMO

Amyloidosis due to deposits of transthyretin (ATTR) is currently considered the most frequent form of cardiac amyloidosis and its incidence is increasing thanks to the advances in diagnostic imaging techniques. Some non-invasive diagnostic criteria have recently been published on this entity that due to the development of new drugs for the specific treatment of cardiac ATTR, have prognostic and therapeutic implications. That is why cardiac ATTR could cease to be a rare disease and become a frequent one, and become potentially treatable instead of incurable. We present the case of an 80-year-old male diagnosed with non-hereditary cardiac ATTR by means of gammagraphy with 99mTc diphosfonate scintigraphy (99mTc-DPD) following the new criteria of non-invasive diagnosis.


Assuntos
Amiloidose/diagnóstico por imagem , Cardiopatias/diagnóstico por imagem , Pré-Albumina , Idoso de 80 Anos ou mais , Humanos , Masculino
5.
An Sist Sanit Navar ; 39(3): 429-432, 2016 12 30.
Artigo em Espanhol | MEDLINE | ID: mdl-28032878

RESUMO

We report the case of a 94-year-old woman with Bouveret's syndrome, where endoscopic treatment was performed. Bouveret's syndrome is a gastric outlet obstruction due to gallstone impaction within the duodenum. It is the least frequent presentation of gallstone ileus. Gallstone ileus is a complication of cholelithiasis and has a high morbidity and mortality. Therefore, it requires an early diagnosis and urgent treatment, which is usually surgical. The peculiarity of this case is that we obtained the full resolution of the symptoms by endoscopic treatment in an elderly patient with high surgical risk.


Assuntos
Endoscopia Gastrointestinal , Cálculos Biliares/complicações , Cálculos Biliares/cirurgia , Obstrução da Saída Gástrica/etiologia , Obstrução da Saída Gástrica/cirurgia , Idoso de 80 Anos ou mais , Feminino , Humanos , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA